*3.7.1 Metabolite technologies*

*Oral Health by Using Probiotic Products*

*3.6.1 Anticandidosis activities*

antimycotics)

type)

action are of availability.

biotopes of the vaginal tract.

and EC 3.4.21., respectively [9])

delivery of potential effector GC on cell surface)

• Delayed degradation of microbial massifs

• Partial directed lysis of microbial massif

cofunctioning to anti-infectious agents (antibiotics, metabiotics, GC) and cells of

We characterize LSSM (acidic, low acidic, cationic: aLL, laLL, cLL, aLB, and cLB) of domestic probiotics which recognize polymeric artificial GC mucin-like analogs of antigens and EPC (fungal and bacterial mannans, bifidobacterial α-L-

• Against intestinal and urogenital *Candida* of epidemiologically significant species of group I (*C. albicans* and *C. tropicalis*: early action of aLB within the first 2 days; delayed action of cLL and LB within 1–2 months; synergism between acidic and cationic LSSM, cLB, and grass lectins, aLSSM/cLSSM, and some

• Against *Candida* of epidemiologically significant species of group II (*C. glabrata*: inhibition of virulent factors such as fungal IgA1 and IgG proteinases, EC 3.4.21.72

• Against *Candida* of epidemiologically significant species of group III (*C. krusei*:

• Interruption of mycosymbiosis parasitism of *Candida—Aspergillus*: the drugs

• Tearing away fragments of massif (by two mechanisms depending on lectin

LSSM possess potential of diagnostics and prognostics of biotope diseases [37]. Results support important principle approach that diseases of MB (as in the case of CBF according to the principle "there is the body—there are diseases") reflect own "biotope diseases" in organism [39]. LSSM can be used in phenotyping prognostics and diagnostics of infectious processes in organism; for prophylaxis and therapy of candidoses, staphylococcoses, mixed fungal-bacterial infections, mixed symbiotic mycoses; innate infections; immunodeficiency and infections against the background of immunodeficiency, upon antibiotics-/chemo-/radiotherapy. Such GC effectors as metabiotics, prebiotics, glycoantigens, and drugs of selective directed

It is of importance to consider the participation of LSSM in supporting biotope mucosal MB in conditions of oxidative stress (cofunctioning of laLL and probiotic oxidoreductase systems) [26]. Panel combinations of LB and LL are perspective in early evaluation (before the inflammation) of status of MB of functionally different

Activities of LSSM against staphylococci (on example of patients *S. aureus*

against candidosis as predictably affective against aspergillosis)

isolates): aLL > aLB; aLL and aLB; LSSM activities accompanied with:

• Synergism between aLL and LB in antistaphylococcal actions

*Antimicrobial directions of LSSM action* were established [26, 31, 38].

organism protective systems (macrophages and leukocytes).

Fuc-containing, sulfated and phosphorylated).

**84**

